CL2011001967A1 - Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. - Google Patents
Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.Info
- Publication number
- CL2011001967A1 CL2011001967A1 CL2011001967A CL2011001967A CL2011001967A1 CL 2011001967 A1 CL2011001967 A1 CL 2011001967A1 CL 2011001967 A CL2011001967 A CL 2011001967A CL 2011001967 A CL2011001967 A CL 2011001967A CL 2011001967 A1 CL2011001967 A1 CL 2011001967A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- inflammatory diseases
- azaheterocyclic
- cancer
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- -1 AMINO Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20735409P | 2009-02-11 | 2009-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001967A1 true CL2011001967A1 (es) | 2012-03-30 |
Family
ID=42199208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001967A CL2011001967A1 (es) | 2009-02-11 | 2011-08-11 | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8637532B2 (enExample) |
| EP (1) | EP2396307B1 (enExample) |
| JP (1) | JP5642714B2 (enExample) |
| KR (1) | KR101699991B1 (enExample) |
| CN (1) | CN102317269B (enExample) |
| AR (1) | AR075396A1 (enExample) |
| AU (1) | AU2010214095B2 (enExample) |
| BR (1) | BRPI1008325A2 (enExample) |
| CA (1) | CA2751886C (enExample) |
| CL (1) | CL2011001967A1 (enExample) |
| DK (1) | DK2396307T3 (enExample) |
| EA (1) | EA020731B1 (enExample) |
| ES (1) | ES2527940T3 (enExample) |
| HR (1) | HRP20141239T1 (enExample) |
| IL (1) | IL214412A0 (enExample) |
| MX (1) | MX338354B (enExample) |
| MY (1) | MY160468A (enExample) |
| NZ (1) | NZ595087A (enExample) |
| PL (1) | PL2396307T3 (enExample) |
| PT (1) | PT2396307E (enExample) |
| SG (1) | SG173473A1 (enExample) |
| SI (1) | SI2396307T1 (enExample) |
| UA (1) | UA107188C2 (enExample) |
| WO (1) | WO2010093419A1 (enExample) |
| ZA (1) | ZA201106624B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| CN103140484B (zh) * | 2010-07-29 | 2015-04-22 | 默克专利有限公司 | 环状胺氮杂杂环甲酰胺 |
| PT2643313T (pt) * | 2010-11-24 | 2016-10-11 | Merck Patent Gmbh | Quinazolina carboxamida azetidinas |
| HRP20171655T1 (hr) | 2011-09-12 | 2017-12-15 | Merck Patent Gmbh | Derivati aminopirimidina za upotrebu kao modulatori aktivnosti kinaze |
| LT2755965T (lt) | 2011-09-12 | 2017-11-10 | Merck Patent Gmbh | Naujieji imidazolo aminai kaip kinazės aktyvumo moduliatoriai |
| PL2794571T3 (pl) * | 2011-12-22 | 2017-04-28 | Merck Patent Gmbh | Nowe heterocykliczne karboksyamidy jako modulatory aktywności kinazowej |
| US9315517B2 (en) | 2012-11-16 | 2016-04-19 | Merck Patent Gmbh | Imidazol-piperidinyl derivatives as modulators of kinase activity |
| WO2014078637A1 (en) | 2012-11-16 | 2014-05-22 | Merck Patent Gmbh | Novel heterocyclic derivatives as modulators of kinase activity |
| ES2821102T3 (es) * | 2012-11-29 | 2021-04-23 | Merck Patent Gmbh | Derivados de azaquinazolincarboxamida |
| RU2721418C2 (ru) | 2013-02-01 | 2020-05-19 | Веллстат Терапьютикс Корпорейшн | Соединения амина, имеющие противовоспалительную, противогрибковую, противопаразитарную и противораковую активность |
| SG10201900954SA (en) | 2013-03-11 | 2019-02-27 | Merck Patent Gmbh | Heterocycles as Modulators of Kinase Activity |
| GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
| RU2733401C2 (ru) | 2014-04-03 | 2020-10-01 | Мерк Патент Гмбх | Комбинации противораковых лекарств |
| CN104292170B (zh) * | 2014-09-22 | 2016-06-29 | 广西师范大学 | 具有抗肿瘤作用的喹唑啉-芳基脲衍生物及其应用 |
| CA2965336A1 (en) * | 2014-10-22 | 2016-04-28 | The Board Of Regents Of The University Of Texas System | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof |
| GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| FR3066761B1 (fr) | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
| WO2019006322A1 (en) * | 2017-06-30 | 2019-01-03 | The University Of North Carolina At Chapel Hill | HETEROCROMATINE GENE REPRESSION INHIBITORS |
| TWI827583B (zh) | 2018-03-08 | 2024-01-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之胺基吡嗪二醇化合物 |
| TWI853814B (zh) * | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| CN109369634B (zh) * | 2018-12-19 | 2021-07-27 | 陕西国际商贸学院 | 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途 |
| RU2723481C1 (ru) * | 2019-10-03 | 2020-06-11 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УНИТАРНОЕ ПРЕДПРИЯТИЕ "ИНСТИТУТ ХИМИЧЕСКИХ РЕАКТИВОВ И ОСОБО ЧИСТЫХ ХИМИЧЕСКИХ ВЕЩЕСТВ НАЦИОНАЛЬНОГО ИССЛЕДОВАТЕЛЬСКОГО ЦЕНТРА "КУРЧАТОВСКИЙ ИНСТИТУТ" (НИЦ "Курчатовский институт - ИРЕА) | 4-[метил 4-(аминометил)циклогексанкарбоксилат]хиназолин и способ его получения |
| MA57518B1 (fr) | 2019-11-01 | 2025-12-31 | Syngenta Crop Protection Ag | Composés hétéroaromatiques bicycliques condensés à activité pesticide |
| CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
| CA3201799A1 (en) | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
| JP2024527287A (ja) | 2021-06-24 | 2024-07-24 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤としての２－［３－［１［（キナゾリン－４－イル）アミノ］エチル］ピラジン－２－イル］チアゾール－５－カルボニトリル誘導体及び類似化合物 |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| CA3245810A1 (en) * | 2022-04-11 | 2023-10-19 | Merck Patent Gmbh | PYRIDO[3,2-D]PYRIMIDINS USED AS HPK1 INHIBITORS |
| JP2025520650A (ja) | 2022-06-21 | 2025-07-03 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物的に活性な縮合二環式芳香族複素環式化合物 |
| CN115521474B (zh) * | 2022-09-30 | 2023-08-22 | 陕西科技大学 | 一种基于五重互穿氢键有机框架材料及其制备方法和应用 |
| WO2025228828A1 (en) * | 2024-04-29 | 2025-11-06 | Merck Patent Gmbh | Carboxamide compounds for the treatment and prevention of viral diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA805652B (en) * | 1979-09-14 | 1981-09-30 | New Zealand Dev Finance | Compounds having antitumour properties |
| GB8804445D0 (en) * | 1988-02-25 | 1988-03-23 | Smithkline Beckman Intercredit | Compounds |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| RU2002110461A (ru) * | 1999-09-21 | 2004-03-10 | Астразенека Аб (Se) | Производные хиназолина и их применение в качестве фармацевтических веществ |
| ATE503743T1 (de) * | 2000-04-27 | 2011-04-15 | Astellas Pharma Inc | Kondensierte heteroarylderivate |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| ES2305081T3 (es) * | 2000-06-28 | 2008-11-01 | Astrazeneca Ab | Derivados de quinozolina sustituidos y su uso como inhibidores. |
| CN100491372C (zh) * | 2001-12-24 | 2009-05-27 | 阿斯特拉曾尼卡有限公司 | 作为欧若拉激酶抑制剂的取代喹唑啉衍生物 |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| CA2522595A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| CA2539339A1 (en) | 2003-09-30 | 2005-04-14 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CA2541989C (en) | 2003-10-24 | 2013-10-01 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| WO2005054237A1 (en) | 2003-11-21 | 2005-06-16 | Novartis Ag | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
| JP2007513962A (ja) | 2003-12-09 | 2007-05-31 | アメリカ合衆国 | 免疫応答を抑制するため、または増殖性障害を治療するための方法 |
| AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5066446B2 (ja) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を予測する方法 |
| TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| US7776857B2 (en) * | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
-
2010
- 2010-02-04 DK DK10705453.8T patent/DK2396307T3/en active
- 2010-02-04 KR KR1020117021335A patent/KR101699991B1/ko active Active
- 2010-02-04 UA UAA201110411A patent/UA107188C2/ru unknown
- 2010-02-04 PL PL10705453T patent/PL2396307T3/pl unknown
- 2010-02-04 SI SI201030849T patent/SI2396307T1/sl unknown
- 2010-02-04 JP JP2011550122A patent/JP5642714B2/ja active Active
- 2010-02-04 HR HRP20141239AT patent/HRP20141239T1/hr unknown
- 2010-02-04 CN CN201080007165.1A patent/CN102317269B/zh active Active
- 2010-02-04 US US13/148,903 patent/US8637532B2/en active Active
- 2010-02-04 EA EA201101182A patent/EA020731B1/ru not_active IP Right Cessation
- 2010-02-04 MY MYPI2011003710A patent/MY160468A/en unknown
- 2010-02-04 AU AU2010214095A patent/AU2010214095B2/en active Active
- 2010-02-04 WO PCT/US2010/000313 patent/WO2010093419A1/en not_active Ceased
- 2010-02-04 MX MX2011008395A patent/MX338354B/es active IP Right Grant
- 2010-02-04 ES ES10705453.8T patent/ES2527940T3/es active Active
- 2010-02-04 PT PT107054538T patent/PT2396307E/pt unknown
- 2010-02-04 EP EP10705453.8A patent/EP2396307B1/en active Active
- 2010-02-04 CA CA2751886A patent/CA2751886C/en active Active
- 2010-02-04 NZ NZ595087A patent/NZ595087A/xx unknown
- 2010-02-04 SG SG2011055001A patent/SG173473A1/en unknown
- 2010-02-04 BR BRPI1008325-1A patent/BRPI1008325A2/pt not_active IP Right Cessation
- 2010-02-11 AR ARP100100376A patent/AR075396A1/es not_active Application Discontinuation
-
2011
- 2011-08-02 IL IL214412A patent/IL214412A0/en active IP Right Grant
- 2011-08-11 CL CL2011001967A patent/CL2011001967A1/es unknown
- 2011-09-09 ZA ZA2011/06624A patent/ZA201106624B/en unknown
-
2013
- 2013-12-13 US US14/105,974 patent/US9040560B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011001967A1 (es) | Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico. | |
| CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| UY31198A1 (es) | Amidas de ácidos benzoicos triazinil sustituidos, composiciones farmacéticas conteniéndolos y aplicaciones. | |
| UY32611A (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| UY32648A (es) | Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades | |
| CR20110270A (es) | Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades | |
| UY32859A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| UY30748A1 (es) | Compuesto0s novedosos | |
| UY32494A (es) | Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones | |
| PA8819201A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| CR20180339A (es) | INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576) | |
| UY32918A (es) | Nuevos compuestos de 2-piridona | |
| ECSP109903A (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| CL2012001971A1 (es) | Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras. | |
| PA8841901A1 (es) | Compuestos orgánicos | |
| UY29803A1 (es) | Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones | |
| DOP2011000076A (es) | Derivados de heteroaril amidas y su uso como activadores de glucoquinasa | |
| CR20120264A (es) | Compuestos | |
| ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| UY33349A (es) | Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos | |
| UA107183C2 (uk) | Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань | |
| UY31905A (es) | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |